On December 9, 2025, Praxis Precision Medicines announced the conversion of its EMBRAVE3 study of elsunersen to a single-arm study for early-onset SCN2A DEE, reducing patient enrollment from 40 to 30. The primary analysis will assess changes in motor seizures after 24 weeks of treatment.